<?xml version="1.0" encoding="UTF-8"?>
<p>Four trials, including 142 cases, investigated the impact of antiviral therapy on HBeAg clearance in HBV-GN patients. We evaluated HBeAg clearance after antiviral therapy, and the heterogeneity using the I
 <sup>2</sup> statistic was 63%, 
 <italic>P</italic> = 0.05. The test for the overall effect was 
 <italic>P</italic>&lt;0.00001 with a random effect model (
 <xref ref-type="fig" rid="pone.0227532.g007">Fig 7</xref>). HBeAg significantly decreased after antiviral therapy (OR = 27.08, 95% CI: 3.71−197.88). A sensitivity analysis was performed and showed that the study by Tang’s study[
 <xref rid="pone.0227532.ref019" ref-type="bibr">19</xref>] was the main factor impacting the results. (
 <xref ref-type="supplementary-material" rid="pone.0227532.s005">S5 Fig</xref>)
</p>
